Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aprea Therapeutics Inc (APRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: APRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.06% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.44M USD | Price to earnings Ratio - | 1Y Target Price 15.67 |
Price to earnings Ratio - | 1Y Target Price 15.67 | ||
Volume (30-day avg) 30367 | Beta 1.57 | 52 Weeks Range 1.85 - 6.48 | Updated Date 04/2/2025 |
52 Weeks Range 1.85 - 6.48 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.35 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.54 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) -1567.43% |
Management Effectiveness
Return on Assets (TTM) -38.39% | Return on Equity (TTM) -66.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12414872 | Price to Sales(TTM) 6.94 |
Enterprise Value -12414872 | Price to Sales(TTM) 6.94 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.35 | Shares Outstanding 5434900 | Shares Floating 4038398 |
Shares Outstanding 5434900 | Shares Floating 4038398 | ||
Percent Insiders 11.62 | Percent Institutions 41.59 |
Analyst Ratings
Rating 4.33 | Target Price 15.67 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aprea Therapeutics Inc
Company Overview
History and Background
Aprea Therapeutics, Inc. is a biopharmaceutical company focusing on developing and commercializing novel cancer therapeutics. It was founded to develop therapies targeting the tumor suppressor protein p53.
Core Business Areas
- Small Molecule Drug Development: Aprea focuses on developing small molecule drugs that reactivate mutant p53, a tumor suppressor protein, in cancer cells. Their lead product candidate is eprenetapopt.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. Organizational structure typically includes research and development, clinical operations, and business development divisions.
Top Products and Market Share
Key Offerings
- Eprenetapopt: A small molecule that reactivates mutant p53 protein. It is currently in clinical trials for various hematologic malignancies and solid tumors. The market share is currently 0% as the product is in clinical trials. Key competitors for hematologic malignancies and solid tumors include major pharmaceutical companies developing targeted therapies and immunotherapies, such as Roche, Novartis, and Merck.
Market Dynamics
Industry Overview
The oncology market is a rapidly growing sector driven by increasing cancer incidence and advancements in treatment options, including targeted therapies and immunotherapies.
Positioning
Aprea is positioned as a company developing novel therapies targeting p53, a key tumor suppressor. Their competitive advantage lies in their focus on this specific target and their lead product candidate, eprenetapopt.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Aprea's TAM depends on the success of eprenetapopt in specific cancer indications. If the drug is approved for a broad range of cancers, its TAM could be significant. Given that Eprenetapopt is in clinical trial, the TAM in relation to the company is low.
Upturn SWOT Analysis
Strengths
- Novel approach targeting p53
- Experienced management team
- Strong intellectual property portfolio
- Positive pre-clinical and clinical data for eprenetapopt in certain cancers
Weaknesses
- Single product pipeline (eprenetapopt)
- High dependence on clinical trial outcomes
- Limited commercial infrastructure
- Currently not profitable
Opportunities
- Expansion of eprenetapopt into new cancer indications
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designation or accelerated approval
- Development of new p53-targeting therapies
Threats
- Clinical trial failures
- Competition from established cancer therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- GILD
- VRTX
Competitive Landscape
Aprea faces strong competition from established pharmaceutical companies with broader portfolios and more advanced pipelines. Its advantage lies in its unique approach targeting p53, but it needs to demonstrate clinical efficacy and secure regulatory approval to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Aprea's historical growth is primarily reflected in its progress through clinical trials and its ability to secure funding.
Future Projections: Future growth depends on the successful development and commercialization of eprenetapopt. Analyst estimates will vary based on clinical trial results and market potential.
Recent Initiatives: Recent initiatives include advancing clinical trials for eprenetapopt in various cancer types and seeking partnerships with other companies.
Summary
Aprea Therapeutics is a development-stage biopharmaceutical company focused on novel cancer therapies. Their lead candidate, eprenetapopt, targets the p53 tumor suppressor. The company faces significant risks associated with clinical trial outcomes. While they have a novel approach, they need to demonstrate clinical efficacy to compete with established players. The future of the company relies on the progress and potential market for eprenetapopt.
Similar Companies
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aprea Therapeutics Inc
Exchange NASDAQ | Headquaters Doylestown, PA, United States | ||
IPO Launch date 2019-10-03 | Co-Founder, CEO, President & Director Dr. Oren Gilad Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aprea.com |
Full time employees 8 | Website https://www.aprea.com | ||
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.